Medicare Cuts Prompt Rise in Laser Cataract Procedures Despite Equivalent Outcomes
Medicare's decade-long 20% cut in cataract surgery fees has fueled growth in laser-assisted procedures that permit extra patient billing, even though evidence shows no outcome advantage. This incentive structure shifts costs to enrollees while practices recoup revenue. Future CMS policy adjustments on refractive services will determine whether the trend persists.
Medicare reimbursement reductions have created clear financial pressure on ophthalmology practices. With the global fee covering pre- and post-operative care now at $520, many surgeons offer femtosecond laser assistance exclusively for premium lens placement or astigmatism correction, allowing separate patient charges of $1,000–$3,000 per eye. Market Scope data show this share rising steadily while traditional scalpel methods remain the covered standard. The policy design permits balance billing only when refractive goals are pursued, directly linking payment cuts to the observed shift in procedure mix.
Multiple studies and the American Academy of Ophthalmology position statement confirm that laser assistance does not reduce complications or improve visual acuity over manual techniques for routine cases. Randomized and observational data in peer-reviewed ophthalmology journals consistently show equivalent safety and refractive outcomes. The AAO explicitly states that evidence has not demonstrated fewer complications or superior results. This equivalence means the added out-of-pocket cost delivers no measurable clinical benefit for most patients yet generates substantial practice revenue.
The pattern reflects broader Medicare dynamics: reimbursement compression for high-volume procedures encourages unbundled or non-covered add-ons. Private insurers and Medicare Advantage plans typically mirror these rules, amplifying the effect. Older adults facing premium lens and laser fees may delay care or accept higher financial burden, raising equity concerns not addressed in current coverage policy. Equipment costs up to $500,000 further concentrate adoption among higher-volume or urban practices.
Continued reimbursement pressure is likely to sustain or accelerate laser uptake unless CMS revises rules on refractive add-ons or ties payment to demonstrated value. Monitoring claims data for changes in patient cost-sharing and procedure mix will clarify whether access disparities widen.
CMS: Laser-assisted share of Medicare cataract procedures exceeds 15% by end of 2027 if current reimbursement trajectory holds.
Sources (3)
- [1]CMS Physician Fee Schedule(https://www.cms.gov/medicare/physician-fee-schedule)
- [2]American Academy of Ophthalmology Clinical Statement(https://www.aao.org/clinical-statement/femtosecond-laser-assisted-cataract-surgery)
- [3]Market Scope Ophthalmic Market Report(https://www.market-scope.com)